ANLNGMHealthcare·Biotechnology#236 in industry

Adlai Nortye Ltd.

+268.1% · 90d

$13.25

-1.55 (-10.47%)

After-Hours $13.94(+0.69)

News

(2)

April 2026

Apr 10, 20262 weeks ago20-FHealthcare

Adlai Nortye Reports $14.7M Working Capital Deficiency

ANLAdlai Nortye Ltd.

# 🧾 What This Document Is This is Adlai Nortye's **annual report** (Form 20-F) for the year ended December 31, 2025. It's a comprehensive filing required by the U.S. SEC for foreign companies listed on American exchanges. Think of it as the company's official "year-in-review" and health check-up, p

Read summaryView on SEC EDGAR

Apr 1, 20263 weeks ago6-KHealthcare

Adlai Nortye Ltd. — 6-K Filing

ANLAdlai Nortye Ltd.

# 🧾 What This Document Is This is a **Form 6-K**, a report that foreign companies listed on U.S. stock exchanges must file with the SEC. Think of it as a "here's what's new" update for investors. This specific filing from April 2026 is all about a significant **management change** at the company.

Read summaryView on SEC EDGAR

Key Data

Market Cap$853.3M

Open$14.57

Prev Close$14.80

Day Range$12.61 – $14.66

52W Range$0.88 – $17.25

Volume545,858

P/E (TTM)—

EPS$-1.11

Dividend Yield—

Beta-0.71

Revenue Growth178.10%

Price Target$29.67(+123.9%)

Analyst Ratings

Strong Buy3 analysts

Buy 3Hold 0Sell 0

About

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick Township, New Jersey.

Healthcare · Biotechnology

109 employees

www.adlainortye.com